Table 1 HPV screening activity and test results by sociodemographic and programmatic characteristics among women screened for cervical cancer in Nicaragua in 2017
From: HPV-based cervical cancer screening in Nicaragua: from testing to treatment
Total | HPV Positive | |||
|---|---|---|---|---|
N | % | N | Prevalence % (95% CI) | |
Total | 44,635 | 100 | 6776 | 15.2 (14.9–15.5) |
Department | ||||
Carazo | 12,261 | 27.5 | 1962 | 16.0 (15.4–16.7) |
Chinandega | 21,333 | 47.8 | 3028 | 14.2 (13.7–14.7) |
Chontales | 11,041 | 24.7 | 1786 | 16.2 (15.5–16.9) |
Age, years | ||||
Mean (SE) | 40.8 (8.6) | N/A | 39.5 (8.5) | N/A |
Median (IQR) | 39.0 (33–47) | N/A | 37.0 (20–71) | N/A |
In target age range (30–59 years) | 44,222 | 99.1 | 6681 | 98.6 |
Out of target age range | 376 | 0.8 | 91 | 1.3 |
< 25 | 39 | 0.09 | 9 | 23.1 (12.4–39.0) |
25–29 | 183 | 0.4 | 47 | 25.7 (19.9–32.5) |
30–34 | 13,255 | 29.7 | 2456 | 18.5 (17.9–19.2) |
35–39 | 9485 | 21.3 | 1459 | 15.4 (14.7–16.1) |
40–44 | 7200 | 16.1 | 1011 | 14.0 (13.3–14.9) |
45–49 | 5744 | 12.9 | 715 | 12.5 (11.6–13.3) |
50–54 | 4700 | 10.5 | 562 | 12.0 (11.1–12.9) |
55–59 | 3838 | 8.6 | 478 | 12.5 (11.4–13.5) |
60+ | 154 | 0.3 | 35 | 22.7 (16.8–30.0) |
Missing | 37 | 0.08 | 4 | 10.8 (4.1–25.8) |
HPV Screening Method | ||||
Self-collected | 43,105 | 96.6 | 6578 | 15.3 (14.9–15.6) |
Provider-collecteda | 637 | 1.4 | 112 | 17.6 (14.8–20.7) |
Unknown | 893 | 2.0 | 86 | 9.6 (7.9–11.7) |